» Articles » PMID: 23676463

Specific Peripheral B Cell Tolerance Defects in Patients with Multiple Sclerosis

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2013 May 17
PMID 23676463
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is a genetically mediated autoimmune disease of the central nervous system. B cells have recently emerged as major contributors to disease pathogenesis, but the mechanisms responsible for the loss of B cell tolerance in patients with MS are largely unknown. In healthy individuals, developing autoreactive B cells are removed from the repertoire at 2 tolerance checkpoints during early B cell development. Both of these central and peripheral B cell tolerance checkpoints are defective in patients with rheumatoid arthritis (RA) and type 1 diabetes (T1D). Here, we found that only the peripheral, but not the central, B cell tolerance checkpoint is defective in patients with MS. We show that this specific defect is accompanied by increased activation and homeostatic proliferation of mature naive B cells. Interestingly, all of these MS features parallel defects observed in FOXP3-deficient IPEX patients, who harbor nonfunctional Tregs. We demonstrate that in contrast to patients with RA or T1D, bone marrow central B cell selection in MS appears normal in most patients. In contrast, patients with MS suffer from a specific peripheral B cell tolerance defect that is potentially attributable to impaired Treg function and that leads to the accumulation of autoreactive B cell clones in their blood.

Citing Articles

Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune System.

Mohsen E, Haffez H, Ahmed S, Hamed S, El-Mahdy T Mol Neurobiol. 2025; .

PMID: 39934561 DOI: 10.1007/s12035-025-04728-5.


Labeling of Bruton's Tyrosine Kinase (BTK) Inhibitor [C]BIO-2008846 in Three Different Positions and Measurement in NHP Using PET.

Nag S, Datta P, Forsberg Moren A, Khani Y, Martarello L, Kaliszczak M Int J Mol Sci. 2024; 25(14).

PMID: 39063112 PMC: 11277166. DOI: 10.3390/ijms25147870.


Chimeric antigen receptor T cell therapy for autoimmune disease.

Chung J, Brudno J, Borie D, Kochenderfer J Nat Rev Immunol. 2024; 24(11):830-845.

PMID: 38831163 DOI: 10.1038/s41577-024-01035-3.


Gut Bacteria Provide Genetic and Molecular Reporter Systems to Identify Specific Diseases.

Dicks L Int J Mol Sci. 2024; 25(8).

PMID: 38674014 PMC: 11050607. DOI: 10.3390/ijms25084431.


EBV infection drives MS pathology: No.

t Hart B, van Luijn M Mult Scler. 2024; 30(4-5):485-487.

PMID: 38602258 PMC: 11010563. DOI: 10.1177/13524585241235833.


References
1.
Arechiga A, Habib T, He Y, Zhang X, Zhang Z, Funk A . Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 2009; 182(6):3343-7. PMC: 2797545. DOI: 10.4049/jimmunol.0713370. View

2.
Nylander A, Hafler D . Multiple sclerosis. J Clin Invest. 2012; 122(4):1180-8. PMC: 3314452. DOI: 10.1172/JCI58649. View

3.
Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-88. DOI: 10.1056/NEJMoa0706383. View

4.
Venken K, Hellings N, Broekmans T, Hensen K, Rummens J, Stinissen P . Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol. 2008; 180(9):6411-20. DOI: 10.4049/jimmunol.180.9.6411. View

5.
Sawcer S, Hellenthal G, Pirinen M, Spencer C, Patsopoulos N, Moutsianas L . Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476(7359):214-9. PMC: 3182531. DOI: 10.1038/nature10251. View